NEW YORK, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Specialty drug discovery company, Innovimmune Biotherapeutics Holding, LLC will present data demonstrating successful treatment of rheumatoid arthritis [RA] in a murine collagen-induced arthritis [CIA] model with its proprietary oral small molecule Retinoic acid receptor-related Orphan Receptor gamma t [RORγt] modulators from their INV-17 portfolio. The results will be presented at the 2014 American College of Rheumatology Annual Meeting in Boston on November 16, 2014 and the abstract available online (http://www.acrannualmeeting.org/abstracts/).
In the CIA study, an INV-17 RORγt modulator lead compound was administered orally for 28 days in a therapeutic regimen following RA disease induction. The data demonstrate that mice treated with INV-17 achieved statistically significant reduction in cumulative arthritis score (p<0.001) as the primary study end-point, in contrast to a vehicle (placebo) group. Significant improvement in clinical disease scores in the INV-17 group began on day 13 (p=0.04), with maximal therapeutic effects observed on day 16 (p=0.0007) through day 26 (p=0.0003) and through the end of the study (p=0.01).
"This is a remarkable finding in that a novel therapeutic approach targeting pathogenic T helper 17 [TH17] cells through RORγt modulation provides superior preclinical treatment efficacy in RA. These results, which demonstrate successful RA disease amelioration in the absence of toxicity, may provide a novel oral disease-modifying antirheumatic drug [DMARD] treatment strategy with an oral INV-17 drug for RA and other TH17-mediated autoimmune diseases," said Ellen M. Ginzler, M.D., M.P.H.; Distinguished Teaching Professor of Medicine and Chief, Division of Rheumatology, SUNY Downstate Medical Center.
RORγt is the master regulator of human TH17 cells that play a critical role in the pathogenesis of several autoimmune diseases. The selection of an oral INV-17 clinical candidate compound is being fast-tracked concurrently for potential therapeutic applications in multiple RORγt-regulated autoimmune diseases with significant unmet medical needs.
"These findings of the successful preclinical therapeutic utility of INV-17 in RA, together with prior efficacy data announced for the successful disease prevention in a murine model of multiple sclerosis (13 J Neurol Sci. Gaweco et al), further strengthen our parallel IND-enabling development and regulatory strategies for multiple autoimmune disease indications of prioritized clinical lead compounds of the INV-17 portfolio. We believe our best-in-class RORγt inhibitors will provide significant treatment advance in several autoimmune diseases, and are strongly encouraged having achieved the second preclinical Proof of Concept for INV-17 in RA," said Anderson Gaweco, M.D., Ph.D., CEO of Innovimmune.
Innovimmune Biotherapeutics Holding, LLC is a New York City-based specialty drug discovery and exploratory development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule New Molecular Entity immunomodulatory drugs for the treatment of autoimmune and immunoinflammatory diseases.
CONTACT: Corporate Inquiries: Anderson Gaweco Innovimmune Biotherapeutics Holding, LLC +1 (718) 282 2814 email@example.com Media Inquiries: Jules Abraham JQA Partners, LLC +1 (917) 885 7378 firstname.lastname@example.orgSource:Innovimmune Biotherapeutics, Inc.